Sunshine Biopharma Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Sunshine Biopharma Inc., a Colorado corporation with principal offices in Montreal, Canada. The report covers events occurring on July 8, 2016, regarding the unregistered sale of equity securities. Although the filing metadata indicates a date of July 8, 2010, the document text explicitly references transactions and dates in 2015 and 2016, and the signature block is dated July 29, 2010, creating a chronological discrepancy within the source text.
Key Financial Metrics and Transaction Details
The filing details the conversion of debt into equity involving a related party, Advanomics Corporation. The transaction involved the cancellation of two convertible notes totaling $835,394 in exchange for the issuance of 321,305,416 shares of Common Stock.
- Total Debt Converted: $835,394
- Shares Issued: 321,305,416 shares of $0.001 par value Common Stock
- Related Party: Advanomics Corporation
- Underlying Assets: U.S. Patent No. 8,236,935 and worldwide patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the anticancer compound Adva-27a.
The filing does not provide revenue, profit, cash flow, or liquidity metrics for the reporting period.
Material Changes and Transaction History
The transaction resulted from a series of amendments to original debt agreements:
- Original U.S. Patent Note: Initially $4,320,000 (2015), amended in December 2015 to a $210,519 convertible note.
- Original Worldwide Patent Note: Initially $12,822,499 (2015), amended in December 2015 to a $624,875 convertible note.
- Capital Increase: On July 6, 2016, the company filed to increase authorized capital to 3 billion Common shares to facilitate the conversion.
- Conversion Event: On July 8, 2016, the notes were automatically converted into shares upon the capital increase.
Guidance, Risks, and Unusual Items
The company relied on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 for this issuance. The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the unregistered sale.
Investor Verification Checklist
- Date Discrepancy: Verify the actual filing date and the validity of the 2010 signature date versus the 2016 transaction dates described in the text.
- Related Party Transaction: Confirm the terms of the relationship with Advanomics Corporation and the valuation of the patents involved.
- Dilution Impact: Assess the impact of issuing 321 million shares on existing shareholder equity.
- Capital Authorization: Confirm the status of the July 6, 2016 amendment to increase authorized capital.